8-K: Owens & Minor to Acquire Rotech Healthcare for $1.36 Billion, Expanding Home-Based Care Reach

Owens & Minor has agreed to acquire Rotech Healthcare for $1.36 billion in cash, a move that significantly expands its presence in the home-based care market.

Summary

• Owens & Minor will acquire Rotech Healthcare for $1.36 billion in cash, with a net purchase price of approximately $1.32 billion after considering tax benefits.
• Rotech is a major provider of home medical equipment, operating in 46 states with around 325 locations and over 4,200 employees.
• In 2023, Rotech generated approximately $750 million in revenue with an EBITDA margin of nearly 30%.
• The acquisition is expected to be neutral to Owens & Minor's adjusted EPS in the first full year and accretive by approximately $0.15 in the second year.
• Owens & Minor anticipates achieving approximately $50 million in synergies by the end of year three, with potential for additional revenue synergies.
• The transaction is expected to close by the end of 2024, subject to customary closing conditions and regulatory approvals.
• Owens & Minor expects to deleverage its balance sheet to below 3.0x within approximately 24 months after closing.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the acquisition, highlighting strategic benefits, financial accretion, and synergy opportunities. The language is optimistic and forward-looking, suggesting confidence in the transaction's success.

Positives

• The acquisition strengthens Owens & Minor's Patient Direct segment by expanding its product offerings and market reach.
• The combined entity will better serve providers and payors through an integrated national network.
• The acquisition enables Owens & Minor to more comprehensively serve patients with chronic conditions.
• There is a significant synergy opportunity of approximately $50 million by the end of year three, with potential for additional revenue synergies.
• The acquisition accelerates the growth path for the Patient Direct segment, aiming for $5 billion in revenue by 2028.

Negatives

• The acquisition will increase Owens & Minor's book leverage to approximately 4.2x at closing.
• The company will need to deleverage to below 3.0x within approximately 24 months of closing.

Risks

• There is a risk that the transaction may not be completed in a timely manner or at all.
• There is a risk of disruption to management's attention from ongoing business operations due to the acquisition.
• The announcement of the transaction could affect relationships with customers, suppliers, and other third parties.
• There is a risk of exceeding the expected costs of the transaction.
• There is a risk of problems arising in successfully integrating the businesses, which may impact operational efficiency.
• There is a risk that the combined company may be unable to achieve synergies or it may take longer than expected to achieve those synergies.

Future Outlook

The acquisition is expected to be neutral to Owens & Minor's adjusted EPS in the first full year and accretive by approximately $0.15 in the second year. Owens & Minor aims to achieve $5 billion in revenue for the Patient Direct segment by 2028.

Management Comments

• Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor, stated that the acquisition aligns with their strategy to expand in the home-based care space.
• Pesicka also highlighted the disciplined approach toward inorganic growth, focusing on strategic fit and value creation.
• Robin Menchen, President & Chief Executive Officer of Rotech, expressed excitement about joining Owens & Minor and believes the combination will benefit patients, providers, payors, and employees.

Industry Context

This acquisition reflects a broader trend of consolidation and growth in the home-based healthcare market, as companies seek to expand their reach and capabilities in this rapidly growing sector.

Comparison to Industry Standards

• The acquisition multiple of 6.3x LTM EBITDA (excluding synergies) is within the range of recent healthcare services transactions.
• Comparable companies in the home medical equipment space have seen similar consolidation activity, indicating a strategic move by Owens & Minor to strengthen its market position.
• The projected synergy target of $50 million by year three is a typical goal for acquisitions of this size, reflecting the potential for cost savings and operational efficiencies.
• The deleveraging target of below 3.0x within 24 months is a common goal for companies undertaking leveraged acquisitions, demonstrating a commitment to financial stability.

Stakeholder Impact

• The acquisition is expected to benefit patients through improved service and a broader range of product offerings.
• Providers and payors will benefit from an integrated national network and a more comprehensive suite of services.
• Employees of both companies are expected to benefit from the combined entity's growth and stability.
• Shareholders are expected to benefit from the long-term growth and value creation opportunities.

Next Steps

• The transaction is subject to customary closing conditions, including the Hart Scott Rodino Act.
• The transaction is expected to close by the end of 2024.
• Owens & Minor will work to integrate Rotech's operations and achieve the projected synergies.
• Owens & Minor will focus on deleveraging its balance sheet to below 3.0x within approximately 24 months of closing.

Key Dates

Keywords

acquisition, home-based care, Rotech Healthcare, Owens & Minor, medical equipment, EBITDA, synergies, Patient Direct, healthcare, debt financing